Clinical trials have begun for ViaCyte's PEC-Direct, an implant that grows insulin-producing cells from stem cells to treat type 1 diabetes patients. If successful, the implant could eliminate the need for these patients to inject themselves with insulin.
Right now, insulin injections are the best way to manage T1D, but this method can be problematic in high-risk cases - patients with hypoglycemia (low glucose) unawareness, for example, may have trouble adjusting their insulin dosage.
Thankfully, researchers all over the world are hard at work looking for a cure that will free T1D patients from their dependence on insulin injections, and now, one group may have found it. Read More>>